multicenter study from Turkey

Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included.Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85).Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib.C1 [Hacioglu, Muhammet Bekir; Kostek, Osman; Erdogan, Bulent; Cicin, Irfan] Trakya Univ, Dept Med Oncol, Med Fac, Edirne, Turkey.[Karabulut, Senem; Tastekin, Didem] Istanbul Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey.[Goksu, Sema Sezgin] Akdeniz Univ, Med Fac, Dept Med Oncol, Antalya, Turkey.[Alandag, Celal] Karadeniz Tech Univ, Med Fac, Dept Med Oncol, Trabzon, Turkey.[Akagunduz, Baran] Dokuz Eylul Univ, Med Fac, Dept Med Oncol, Izmir, Turkey.[Bilgetekin, Irem] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Med Oncol, Ankara, Turkey.[Caner, Burcu; Sahin, Ahmet Bilgehan] Uludag Univ, Med Fac, Dept Med Oncol, Bursa, Turkey.[Yildiz, Birol] Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey.[Kose, Fatih] Baskent Univ, Adana Med Fac, Dept Med Oncol, Adana, Turkey.[Kaplan, Muhammet Ali] Dicle Univ, Med Fac, Dept Med Oncol, Diyarbakir, Turkey.[Gulmez, Ahmet] Inonu Univ, Med Fac, Dept Med Oncol, Malatya, Turkey.[Dogan, Ender] Erciyes Univ, Med Fac, Dept Med Oncol, Kayseri, Turkey.[Kilickap, Saadettin] Hacettepe Univ, Med Fac, Dept Med Oncol, Ankara, Turkey.[Guven, Deniz Can; Gurbuz, Mustafa] Ankara Univ, Med Fac, Dept Med Oncol, Ankara, Turkey.[Ergun, Yakup] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey.[Karaagac, Mustafa] Necmettin Erbakan Univ, Med Fac, Dept Med Oncol, Konya, Turkey.[Demiray, Atike Gokcen] Pamukkale Univ, Med Fac, Dept Med Oncol, Denizli, Turkey.[Turker, Sema] DiskapiYildir Beyazit Training & Res Hosp, Dept Med Oncol, Ankara, Turkey.[Sakalar, Teoman] Sakarya Univ Training & Res Hosp, Dept Med Oncol, Aksaray, Turkey.[Ozkul, Ozlem] Sakarya Univ Training & Res Hosp, Dept Med Oncol, Sakarya, Turkey.[Telli, Tugba Akin] Marmara Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey.[Sahin, Suleyman] Van Training & Res Hosp, Dept Med Oncol, Van, Turkey.[Bilici, Ahmet] Medipol Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey

Committee of the Turkish Oncology Group (TOG)

Objective Fear of cancer recurrence (FCR) is an important psychological trauma associated with reduction in the quality of life, disruptions in the level of adjustment, emotional distress and anxiety. The purpose of the study was to evaluate the impact of patient-physician relationship on FCR. Methods The study was designed as a multicentre survey study. The cancer survivors, who were under remission, were evaluated with structured questionnaires. Patient-physician relationship (PPR) scale in which higher scores indicate better relationship and FCR inventory was used. Results Between January and April 2019, 1,580 patients were evaluated. The median age was 57.0 (19-88), and 66% were female. There was high level of FCR scores in 51% of participants. There was a negative correlation between PPR and FCR scores (r = -.134,p < .001). In multivariate analysis, young age, female gender, history of metastasectomy and worse PPR were associated with high levels of FCR. Conclusion It is the first data showing the adverse impact of worse PPR on FCR. The strategies to improve the PPR should be practised. In addition, the cancer survivors, who are under the risk of FCR, should be evaluated and managed.C1 [Alkan, Ali; Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Sch Med, Med Oncol, Mugla, Turkey.[Yasar, Arzu; Gurbuz, Mustafa; Senler, Filiz Cay] Ankara Univ, Med Oncol, Sch Med, Ankara, Turkey.[Guc, Zeynep Gulsum; Yavuzsen, Tugba] Dokuz Eylul Univ, Sch Med, Med Oncol, Izmir, Turkey.[Basoglu, Tugba; Yumuk, Perran Fulden] Marmara Univ, Sch Med, Med Oncol, Istanbul, Turkey.[Goksu, Sema Sezgin; Coskun, Hasan Senol] Akdeniz Univ, Med Oncol, Sch Med, Antalya, Turkey.[Basal, Fatma Bugdayci; Ates, Ozturk] Abdurrahman Yurtarslan Res & Training Hosp, Med Oncol, Ankara, Turkey.[Turk, Haci Mehmet] Bezmialem Univ, Sch Med, Med Oncol, Istanbul, Turkey.[Ozdemir, Ozlem] Izmir Bozyak Res & Training Hosp, Med Oncol, Izmir, Turkey.[Cinkir, Havva Yesil] Gaziantep Univ, Sch Med, Med Oncol, Gaziantep, Turkey.[Guven, Deniz Can] Hacettepe Univ, Med Oncol, Sch Med, Ankara, Turkey.[Kus, Tulay] Dr Ersin Arslan Training & Res Hosp, Med Oncol, Gaziantep, Turkey.[Turker, Sema] Diskapi Yildirim Beyazit Res & Training Hosp, Med Oncol, Ankara, Turkey.[Koral, Lokman] Canakkale Onsekiz Mart Univ, Sch Med, Med Oncol, Canakkale, Turkey.[Karakas, Yusuf] Bodrum Acibadem Hosp, Med Oncol, Mugla, Turkey.[Ak, Naziye] Istanbul Univ, Sch Med, Med Oncol, Istanbul, Turkey.[Paydas, Semra] Cukurova Univ, Med Oncol, Sch Med, Adana, Turkey.[Karci, Ebru] Bagcilar Res & Training Hosp, Med Oncol, Istanbul, Turkey.[Demiray, Atike Gokcen] Pamukkale Univ, Med Oncol, Sch Med, Denizli, Turkey.[Demir, Atakan] Acibadem Maslak Hosp, Med Oncol, Istanbul, Turkey.[Alan, Ozkan] Tekirdag Publ Hosp, Med Oncol, Tekirdag, Turkey.[Keskin, Ozge] Selcuk Univ, Sch Med, Med Oncol, Konya, Turkey.[Nayir, Erdinc] VM Med Pk Mersin Hosp, Med Oncol, Mersin, Turkey.[Turhal, Serdar] Anadolu Med Ctr, Med Oncol, Kocaeli, Turkey

Synthesis of benzylidenemalononitrile by Knoevenagel condensation through monodisperse carbon nanotube-based NiCu nanohybrids

Monodisperse nickel/copper nanohybrids (NiCu@MWCNT) based on multi-walled carbon nanotubes (MWCNT) were prepared for the Knoevenagel condensation of aryl and aliphatic aldehydes. The synthesis of these nanohybrids was carried out by the ultrasonic hydroxide assisted reduction method. NiCu@MWCNT nanohybrids were characterized by analytical techniques such as X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), transmission electron microscopy (TEM), high-resolution transmission electron microscopy (HR-TEM), and Raman spectroscopy. According to characterization results, NiCu@MWCNT showed that these nanohybrids form highly uniform, crystalline, monodisperse, colloidally stable NiCu@MWCNT nanohybrids were successfully synthesized. Thereafter, a model reaction was carried out to obtain benzylidenemalononitrile derivatives using NiCu@MWCNT as a catalyst, and showed high catalytic performance under mild conditions over 10-180 min.Dumlupinar UniversityDumlupinar University [2014-05, 2015-35, 2015-50]; Duzce UniversityDuzce University [2015.26.04.371]The authors would like to thank Dumlupinar University (2014-05, 2015-35, and 2015-50) and Duzce University (grant no. 2015.26.04.371) for funding.WOS:0005563883000122-s2.0-85088705103PubMed: 3272817